Mutya Harsch has served as the Chief Legal Officer, General Counsel, and Corporate Secretary of VYNE Therapeutics Inc. (Nasdaq: VYNE) since March 2020. Prior to this, Ms. Harsch served as the General Counsel and Chief Legal Officer of Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), which was acquired in March 2020. In addition, Ms. Harsch served on the board of directors of Satsuma Pharmaceuticals Inc. (Nasdaq: STSA) from October 2021 until its acquisition in April 2023. She also served on the board of directors of the Montclair YMCA until 2022. Ms. Harsch has over 20 years of legal experience, previously holding positions as Special Counsel, Mergers & Acquisitions at Cooley LLP from 2015 to 2017 and as a corporate lawyer at Davis Polk & Wardwell from 2005 to 2015 and from 1999-2003. Ms. Harsch received her J.D. and B.A. from the University of California at Berkeley.